Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: Diabet Med. 2015 Jan 7;32(5):657–664. doi: 10.1111/dme.12664

FIGURE 3.

FIGURE 3

Effect of treatment with placebo or muraglitazar on expression of peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α and genes involved in mitochondrial function. The dashed line indicates no change in gene expression. *P < 0.05 versus pre-treatment. †P < 0.05 for the comparison between muraglitazar and placebo therapy-treated groups. Data are shown as means ± se. COX6C, cytochrome c oxidase subunit VIc; CYB5, cytochrome b5 type B; GATM, glycine amidinotransferase; MEF2C, myocyte enhancer factor 2C; NDUFA5, NADH dehydrogenase (ubiquinone) 1-alpha subcomplex, 5; NQO1, NAD(P)H dehydrogenase, quinine 1; NRF1, nuclear respiratory factor 1; NRF2, nuclear respiratory factor 2; PGC-1b, peroxisome proliferator-activated receptor gamma coactivator-1 beta; SIRT1, sirtuin 1; SOD2, superoxide dismutase 2; TFAM, transcription factor A, mitochondrial; VDAC1, voltage-dependent anion channel 1.